How to Identify and Classify Serious Adverse Events in Clinical Research

Accurate identification of serious adverse events (SAEs) is fundamental to safeguarding participants in clinical trials. SAEs require expedited reporting and rigorous documentation due to their potential impact on subject safety and investigational product evaluation. This guide outlines the standard criteria used globally to define SAEs, supported by regulatory references and industry best practices.

What is a Serious Adverse Event?

According to the ICH E6(R2) and ICH E2A guidelines, a serious adverse event (SAE) is an adverse event (AE) that meets at least one of the following seriousness criteria. It is critical to distinguish SAEs from general AEs to comply with mandatory safety reporting timelines.

Standard Criteria for SAE Classification:

An adverse event is considered “serious” if it results in any of the following:

1. Death: Any AE that leads directly or indirectly to the death of a participant.
2. Life-Threatening: An event where the subject was at immediate risk of death at the time of the event (not hypothetically).
3. Hospitalization: Any unplanned inpatient admission or extension of existing hospitalization.
4. Persistent or Significant Disability/Incapacity: Events that cause permanent or substantial disruption of a person’s ability to conduct normal life functions.
5. Congenital Anomaly/Birth Defect: Observed in offspring of a subject exposed to the study drug.
6. Medically Important Event: Events that may not be immediately life-threatening but require intervention to prevent one of the outcomes listed above.

Understanding Medically Important Events:

This SAE category is often misunderstood. Medically important events can include:

• Seizures that do not result in hospitalization but require urgent treatment
• Intensive care unit (ICU) admission
• Events that jeopardize the subject or require medical/surgical intervention

Refer to the EMA or USFDA guidance for interpretation of this catch-all category.

Distinction Between Severity and Seriousness:

Many clinical teams confuse these terms:

• Severity refers to the *intensity* of the AE (e.g., mild, moderate, severe)
• Seriousness relates to the *outcome* or action criteria that make it reportable as an SAE

For example, a mild allergic reaction causing overnight hospitalization may be an SAE due to hospitalization, despite low severity.

Examples of SAEs in Clinical Settings:

• Death from unexpected cardiac arrest (SAE: Death)
• Severe hypotension requiring ICU care (SAE: Life-Threatening)
• Seizure requiring urgent treatment (SAE: Medically Important)
• Hospitalization for asthma exacerbation (SAE: Hospitalization)
• Congenital heart defect in infant born to study subject (SAE: Birth Defect)

Sites can use StabilityStudies.in to access logs and training aids for SAE classification across ongoing studies.

How Investigators Assess Seriousness:

At the site level, the Principal Investigator (PI) evaluates every AE to determine if it qualifies as “serious.” A seriousness checkbox is typically available in the AE eCRF. If marked, it triggers the SAE reporting process to the sponsor.

Steps for Site-Level SAE Assessment:

1. Review AE details and medical records
2. Check if outcome matches any of the six seriousness criteria
3. Document justification in the source
4. Complete the SAE form in the EDC or sponsor portal
5. Submit within 24 hours to sponsor

For example, a hospital stay for chest pain, even if precautionary, must be evaluated against the “Hospitalization” criterion.

Sponsor Review and Pharmacovigilance Evaluation:

Once the site reports the SAE, the sponsor’s safety team reviews it for:

• Completeness of the report
• Expectedness (per Investigator Brochure)
• Seriousness assessment accuracy
• Coding via MedDRA
• Potential signal detection

Expedited reports such as SUSARs are submitted to health authorities based on seriousness and unexpectedness.

Common Errors in SAE Classification:

• Marking an AE as “severe” but not assessing for seriousness
• Missing hospitalization documentation
• Confusing planned procedures with SAE hospitalization
• Delaying sponsor notification beyond 24 hours

SAE Checklist for Investigators:

• [ ] Does the AE meet any of the six seriousness criteria?
• [ ] Is there documentation in the source file to support the classification?
• [ ] Has the SAE been reported in the EDC and to the sponsor within 24 hours?
• [ ] Have supportive documents been uploaded (e.g., labs, discharge summaries)?
• [ ] Was causality assessed?

Training and SOP Alignment:

Sites should maintain SOPs and periodic training logs on SAE classification and reporting. Utilize templates from Pharma SOPs to define SAE identification workflows, roles, and escalation timelines.

Regulatory Requirements for SAE Reporting:

SAEs must be reported to sponsors and Ethics Committees per local and global guidelines:

• Sponsor: Within 24 hours
• IRB/IEC: As per their SOP (typically 7–15 days)
• Health Authorities: Expedited timelines vary by region

Conclusion:

Understanding the criteria for classifying serious adverse events ensures accurate safety reporting and regulatory compliance in clinical trials. By training site staff, utilizing structured documentation, and applying regulatory definitions consistently, trial sponsors and investigators can confidently navigate the complexities of SAE management while prioritizing participant safety.